Bayers, Raised

Bayer's Raised Guidance Now Faces Its Toughest Audience: The Full-Year Print

Published on 11/19/2026 at 20:01 | Editorial boerse-global.de
Berenberg lifted its Bayer price target to EUR 62 but kept a Hold rating, putting the focus on whether group EBITDA before special items hits the raised 2026 guidance.
Bayers, Raised, Guidance, Now, Faces, Its, Toughest, Audience, The, Full-Year Illustration mit AI erstellt.

Bayer has spent the past few weeks handing investors reasons to feel good about the pipeline. The market's next question is blunter: can the operating numbers carry the share price that has already run up?

Two fresh drug approvals and an upgraded outlook have done the heavy lifting on sentiment. What has not yet been delivered is proof — in hard reported figures — that the improved guidance reflects genuine earnings power rather than a conveniently timed reset of expectations.

Berenberg lifts the target, keeps the rating

Analyst Sebastian Bray raised his price target on Bayer to EUR 62.00 from EUR 53.50 on Tuesday, while leaving his rating at "Hold." The split verdict is the tell. Bray is willing to pay up for the stock on paper, but he is not prepared to tell clients to buy it.

His reasoning leans on what he considers a strong year for Bayer so far, with a possible later listing of Monsanto cited as an additional lever. Proceeds from such a move could, in his view, be channeled into pharmaceutical development.

The distinction matters. A higher target with an unchanged rating says more about where the analyst thinks the stock can drift than about whether he wants to own it. For anyone tracking Bayer, the operating performance now carries more weight than the new number itself.

Should investors sell immediately? Or is it worth buying Bayer?

The benchmark that actually counts

Strip out one-offs and the metric that matters is group EBITDA before special items. Early in November, Bayer lifted its 2026 guidance for that figure to a range of EUR 9.8 billion to EUR 10.3 billion.

Where the company lands inside that band will tell investors whether the raised bar is being cleared with room to spare or merely touched. A result at the top end would support the case that the upgrade was more than a marginal nudge.

For the third quarter of 2026, Bayer reported group revenue of EUR 10.053 billion and EBITDA before special items of EUR 1.615 billion. Those two numbers answer different questions. Revenue shows how much business Bayer booked. The operating profit line shows how much of it stuck — and it is the latter that will determine whether the new guidance holds up.

Two approvals, one open question

The regulatory wins arrived in quick succession. In the past week, the US Food and Drug Administration cleared Asundexian, marketed as Sunharbo, to reduce the risk of recurrent stroke when used alongside an antiplatelet therapy. Bayer describes it as the first FXIa inhibitor approved anywhere in the world.

Shortly before that, in early November, China approved Sevabertinib as a first-line treatment for HER2-mutant non-small cell lung cancer. Bayer also raised its margin outlook for the pharmaceutical division at the same time as the group guidance.

Approval, however, is not the same as uptake. Both green lights cover tightly defined indications, and how quickly the therapies are adopted in those settings — and how much they ultimately contribute to earnings — is a separate matter from the regulator's sign-off. A slower commercial rollout could mean a thinner earnings contribution even if the group forecast survives intact.

The more constructive scenario requires the new treatments to gain traction in the market while the higher margin expectation is met. That combination would send a stronger signal than rising pharma revenue on its own, because it would indicate the additional business is feeding through to profitability rather than just to the top line.

Bayer at a turning point? This analysis reveals what investors need to know now.

Why the downside case doesn't need a miss

The bearish path does not require Bayer to fall short of its annual guidance. A result inside the range could still disappoint if the company only reaches the bottom end and the pharma division offers no convincing evidence of further earnings improvement.

In that event, the debate shifts from whether Bayer hit its numbers to whether those numbers are a platform for growth. After a rally, that is a harder test than simple delivery.

The full-year report is the first real answer

As long as group EBITDA before special items stays on track toward the upgraded range, the outlook underpins expectations of stronger operating profit. Mounting evidence of a top-end outcome, paired with confirmation of the pharma margin target, would give the share price a firmer footing. Signs of a bottom-end result would put the future earnings contribution of the new therapies squarely back in focus.

The 2026 annual figures will settle the first question directly: where within the guidance range does reported group EBITDA before special items actually land? The longer-term verdict depends on what comes next — whether the progress in pharmaceuticals shows up in the operating result.

Ad

Bayer Stock: New Analysis - 19 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70537869 |